Web Exclusives

Minimal residual disease assessments are increasingly being used in the clinical trial setting. Read Article ›

Updated analysis of IKEMA showed improved responses with isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Read Article ›

Ciltacabtagene autoleucel has been shown to have compelling survival benefit, and a new study shows improved health-related quality of life in patients with triple-class exposed multiple myeloma. Read Article ›

Final analysis of ICARIA-MM supports isatuximab plus pomalidomide and dexamethasone as standard of care in patients with relapsed/refractory multiple myeloma. Read Article ›

Continuing medical education and nursing continuing professional development–approved activities can improve clinicians’ knowledge of the fast-emerging treatment landscape in multiple myeloma. Read Article ›

Daratumumab plus lenalidomide and dexamethasone showed deep clinical responses in patients who continued treatment for ≥18 months. Read Article ›

Final results from the LYRA study demonstrate daratumumab plus cyclophosphamide, bortezomib, dexamethasone was well-tolerated and effective in patients with newly diagnosed or relapsed/refractory multiple myeloma. Read Article ›


Better understanding of physician decision factors when selecting therapy for patients with refractory multiple myeloma may facilitate adoption of a wider variety of new treatment options. Read Article ›

Subanalysis strongly supports the use of isatuximab plus carfilzomib and dexamethasone regardless of prior lines of therapy or refractory status to lenalidomide and bortezomib. Read Article ›

Integrating a pharmacist into the care team can have substantial clinical and financial benefits in the setting of relapsed/refractory multiple myeloma and anti-CD38 antibodies. Read Article ›

Carfilzomib plus dexamethasone and daratumumab show improved responses compared with carfilzomib plus dexamethasone in patients with relapsed/refractory multiple myeloma regardless of cytogenetic risk. Read Article ›

Page 1 of 19

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: